Skip to main content

21st Century Advances in Type 1 Diabetes Research and Immunotherapy

65kviews
Editorial12 May 2023
Editorial: 21st century advances in type 1 diabetes research and immunotherapy

The immunology of human type 1 diabetes (T1D) is complex and lacks detailed understanding. Rodent models of disease recapitulate certain molecular and genetic aspects of human disease but have not yielded high quality molecular targets to prevent or reverse progressive pancreatic beta-cell destruction. The predominant paradigm for the past 30 years of hypothesis-driven research is that a handful of carefully identified auto-antigens (both beta-cell specific and non-specific) might be able to induce tolerance in individuals at high risk for developing T1D (typically first-degree relatives of T1D subjects who have multiple T1D autoantibodies). Tolerance induction has been used successfully for decades in allergy immunotherapy, but so far has not been translated over to T1D. Such studies include major immunotherapy trials with insulin, insulin peptides, and glutamic acid decarboxylase 65 (GAD; a major T1D autoantigen). New research suggests that immune-mediated T1D might not follow a single molecular roadmap but develops through a variety of derangements culminating in beta-cell destruction. Moreover, novel neoantigens have been discovered with enhanced T-cell reactivity that might prove to be better for inducing tolerance. While antigen-specific immunotherapy for T1D has yet to demonstrate clinical success, autoantibodies continue to be useful tools for identifying at risk individuals and T1D subtypes.In this special issue of Frontiers, Peng and colleagues define three subtypes of diabetes in their large multi-institutional Chinese cohort: latent autoimmune diabetes in youth (LADY; age between ≥15 to <30 years, no ketoacidosis and insulin independence for 6 months, disease duration < 1 year, and autoantibody positive with either GAD, IA-2A, or ZnT8A), latent autoimmune diabetes in adults (LADA; age >30 years, no ketoacidosis and insulin independence for 6 months, disease duration <1 year, and autoantibody positive with either GAD, IA-2A, or ZnT8A) and type 2 diabetes (>30 years, disease duration <1 year, and autoantibody negative). Using epitope specific GAD assays that identified Cterminal, Middle region, and N-terminal autoantibodies, they determined that young T1D (<15 years), LADY, and old T1D (≥15 and <30 years) subjects had higher reactivity to multiple GAD epitopes than LADA patients. Moreover, T1D and LADY subjects had more high-risk susceptibility alleles for disease than LADA subjects. The authors suggest that different immune activity exists between T1D and LADA subjects https://doi.org/10.3389/fimmu.2022.836952.LADA has been defined primarily in Caucasian populations, but less so in Asian populations. With a population of ~ 1.4 billion people, China has a growing number of individuals with diabetes. Qiu and coauthors performed a systematic review of epidemiology, clinical characteristics, genetics, and immunology of LADA in this growing Chinese population. Importantly, they note that high risk allele HLA DR9/DR9 in Chinese LADA contrasts the well-established DR3/DR4 in Caucasian populations. In addition, GAD antibody positivity was only ~75% in Chinese LADA subjects compared to 90-95% in Caucasian disease. Additional features of LADA in China are well described including clinical manifestations and treatment options https://doi.org/10.3389/fimmu.2022.977413. Pathogenic effector T-cells (both CD4 + and CD8 + ) infiltrate the pancreatic islets in T1D. Identification of autoantigens that stimulate pathologic T cells has become a highly valued research endeavor. Li and colleagues used NOD mice as a T1D model to demonstrate the utility of a novel monoclonal antibody that targets the highly diabetogenic islet amyloid polypeptide (IAPP) K20. The K20 peptide is formed from IAPP that undergoes post-translational modification through a disulfide bridge between two cysteine residues and thereby becomes an autoantigen for the diabetic T cell clone BDC 5.2.9. LD96.24 is a monoclonal antibody that recognizes the IA g7 -K20 disulfide loop thereby blocking its interaction with the BDC T cell receptor. When prediabetic and newly diabetic NOD mice were treated with this monoclonal antibody disease prevention was sustained for the treatment duration https://doi.org/10.3389/fimmu.2022.877022.The B-chain of insulin (amino acid sequence B:9-23) has been considered a predominant autoantigen in T1D. Wenzlau and Haskins present exciting new data about a post translational modified (PTM) hybrid insulin peptide (HIP) called HIP6.3 that results from the fusion of insulin B:9-23 with a ProSAAS sequence (ProSASS is an endogenous inhibitor of prohormone convertase). When used in a stimulation assay with the highly diabetogenic T cell clone BDC-6.9, this neoantigen generated a 4 to 5-fold increased interferon-gamma response. This neoantigens generates more inflammation and immunity in T1D than conventional antigens https://doi.org/10.3389/fimmu.2022.926650.Under appreciated is the role of lymphotoxins (LTs) in immune inflammatory disease. Liu and Wang provide a comprehensive overview of LTs and their indirect role in cytotoxicity towards pancreatic beta cells. LTs mediate formation of tertiary lymphoid organs that are seen in NOD mice and perhaps play a role in T cell recruitment to the pancreatic islets https://doi.org/10.3389/fimmu.2022.917577.In addition, Yang and colleagues present an elegant and comprehensive review of post-translational modification (PTM) of proteins in autoimmunity and beta cell metabolism. This detailed publication provides a fundamental roadmap for understanding metabolic changes that create neo-antigens, alter Tcell metabolism, and improve biomarker sensitivity in T1D and autoimmune conditions. Highlights include detailed explanations of peptide citrullination, T-cell transition from oxidative phosphorylation to glycolytic metabolism, and PTM of novel T1D biomarkers. This is a must read https://doi.org/10.3389/fimmu.2022.1028130.Turning to clinical correlates between effector T cells and T1D progression, T cell metabolism was assessed in T1D subjects over 36 months. Complex interactions occur between cellular metabolism of glucose or fatty acid and T cell function. Simplistically stated, effector T cells have increased autoreactivity when their metabolic program uses glucose rather than fatty acids. Tang and associates evaluated glucose and fatty acid metabolism in CD4 + and CD8 + T cells from 86 Chinese T1D subjects and 45 non-diabetic controls and followed them for 3 years. T1D subjects with low T cell glucose uptake at entry maintained higher c-peptide levels and beta cell function compared to those individuals with high glucose uptake. Therefore, T-cell metabolism now appears to be an important component of sustained autoimmunity in T1D https://doi.org/10.3389/fimmu.2022.897047.Last, the bacterial flora in the gut plays an important role in T1D susceptibility through host-microbe interactions. Studies in monozygotic twins show discordance in T1D development which suggests that non-genomic factors play a role in the disease. It is proposed that altered microbiome in the gut leads to proinflammatory responses through numerous mechanisms including direct signaling from bacterial metabolic products to receptors that regulate immune responses in the human host. Therefore, one twin might have a different microbiome than the other twin and perhaps, a different immune system response. Host-microbiota interactions in T1D is extensively reviewed by Majumdar and Bettini as a capstone for this special edition https://doi.org/10.3389/fimmu.2022.974178.

2,009 views

Latent autoimmune diabetes in adults in China
REVIEW
25 August 2022
Latent autoimmune diabetes in adults in China
Junlin Qiu, 3 more and Zhiguang Zhou
Latent autoimmune diabetes in adults (LADA) is a type of diabetes caused by slowly progressing autoimmune damage to pancreatic beta cells. According to the etiological classification, LADA should belong to the autoimmune subtype of type 1 diabetes (T1D); however, after many years of research, scientists have come to the agreement that this type of diabetes is a distinct diabetes subtype. Multicenter studies have been conducted in different countries worldwide, but it is still unclear how the Chinese and Caucasian populations differ. The epidemiology and phenotypic characteristics of LADA may vary between Caucasian and Chinese diabetic patients as lifestyle, food habits, and body mass index differ between these two populations. The prevalence of LADA in China has reached a high level compared to other countries, and the number of patients ranks first in the world. Previous studies have found general immune genetic effects associated with LADA, but there are also some racial differences. The prevalence of LADA among newly diagnosed type 2 diabetes (T2D) patients over the age of 30 years in China is 5.9%, and LADA patients account for 65% of the newly diagnosed T1D patients in the country. As a country with a large population, China has many people with LADA. A summary and analysis of these studies will enhance the further understanding of LADA in China. In addition, comparing the similarities and differences between the Chinese and the Caucasian population from the perspectives of epidemiology, clinical, immunology and genetics, will help to improve the understanding of LADA, and then promote LADA studies in individual populations.

9,162 views

20 citations

Type-1 Diabetes (T1D) is a complex polygenic autoimmune disorder involving T-cell driven beta-cell destruction leading to hyperglycemia. There is no cure for T1D and patients rely on exogenous insulin administration for disease management. T1D is associated with specific disease susceptible alleles however, the predisposition to disease development is not solely predicted by them. This is best exemplified by the observation that a monozygotic twin has just a 35% chance of developing T1D after their twin’s diagnosis. This makes a strong case for environmental triggers playing an important role in T1D incidence. Multiple studies indicate that commensal gut microbiota and environmental factors that alter their composition might exacerbate or protect against T1D onset. In this review, we discuss recent literature highlighting microbial species associated with T1D. We explore mechanistic studies which propose how some of these microbial species can modulate adaptive immune responses in T1D, with an emphasis on T-cell responses. We cover topics ranging from gut-thymus and gut-pancreas communication, microbial regulation of peripheral tolerance, to molecular mimicry of islet antigens by microbial peptides. In light of the accumulating evidence on commensal influences in neonatal thymocyte development, we also speculate on the link between molecular mimicry and thymic selection in the context of T1D pathogenesis. Finally, we explore how these observations could inform future therapeutic approaches in this disease.

6,735 views

10 citations

Insulin is considered to be a key antigenic target of T cells in Type 1 Diabetes (T1D) and autoimmune diabetes in the NOD mouse with particular focus on the B-chain amino acid sequence B:9-23 as the primary epitope. Our lab previously discovered that hybrid insulin peptides (HIPs), comprised of insulin C-peptide fragments fused to other -cell granule peptides, are ligands for several pathogenic CD4 T cell clones derived from NOD mice and for autoreactive CD4 T cells from T1D patients. A subset of CD4 T cell clones from our panel react to insulin and B:9-23 but only at high concentrations of antigen. We hypothesized that HIPs might also be formed from insulin B-chain sequences covalently bound to other endogenously cleaved ß-cell proteins. We report here on the identification of a B-chain HIP, termed the 6.3HIP, containing a fragment of B:9-23 joined to an endogenously processed peptide of ProSAAS, as a strong neo-epitope for the insulin-reactive CD4 T cell clone BDC-6.3. Using an I-Ag7 tetramer loaded with the 6.3HIP, we demonstrate that T cells reactive to this B-chain HIP can be readily detected in NOD mouse islet infiltrates. This work suggests that some portion of autoreactive T cells stimulated by insulin B:9-23 may be responding to B-chain HIPs as peptide ligands.

5,687 views

28 citations

Enhanced T Cell Glucose Uptake Is Associated With Progression of Beta-Cell Function in Type 1 Diabetes
ORIGINAL RESEARCH
23 May 2022
Enhanced T Cell Glucose Uptake Is Associated With Progression of Beta-Cell Function in Type 1 Diabetes
Rong Tang, 4 more and Xia Li
Background: Abnormal intracellular glucose/fatty acid metabolism of T cells has tremendous effects on their immuno-modulatory function, which is related to the pathogenesis of autoimmune diseases. However, the association between the status of intracellular metabolism of T cells and type 1 diabetes is unclear. This study aimed to investigate the uptake of glucose and fatty acids in T cells and its relationship with disease progression in type 1 diabetes. Methods: A total of 86 individuals with type 1 diabetes were recruited to detect the uptake of glucose and fatty acids in T cells. 2-NBDG uptake and expression of glucose transporter 1 (GLUT1); or BODIPY uptake and expression of carnitine palmitoyltransferase 1A(CPT1A) were used to assess the status of glucose or fatty acid uptake in T cells. Patients with type 1 diabetes were followed up every 3-6 months for 36 months, the progression of beta-cell function was assessed using generalized estimating equations, and survival analysis was performed to determine the status of beta cells function preservation (defined as 2-hour postprandial C-peptide >200 pmol/L). Results: Patients with type 1 diabetes demonstrated enhanced intracellular glucose uptake of T cells as indicated by higher 2NBDG uptake and GLUT1 expression, while no significant differences in fatty acid uptake were observed. The increased T cells glucose uptake is associated with lower C-peptide and higher hemoglobin A1c levels. Notably, patients with low T cell glucose uptake maintained high levels of C-peptide within 36 months of the disease course (fasting C-petite and 2-hour postprandial C-peptide are 60.6 (95%CI: 21.1-99.8) pmol/L and 146.3 (95%CI: 14.1-278.5) pmol/L higher respectively), And they also have a higher proportion of beta-cell function preservation during this follow-up period (P<0.001).

4,832 views

12 citations

GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY)
ORIGINAL RESEARCH
9 March 2022
GAD65 Antibody Epitopes and Genetic Background in Latent Autoimmune Diabetes in Youth (LADY)
Yiman Peng, 11 more and Zhiguang Zhou
Epitope-specific GAD65Abs and HLA-DR-DQ gene assays help improve the value of risk stratification in autoimmune diabetes mellitus and protect islet function. Identification and early intervention are important for latent autoimmune diabetes in youth (LADY). The aims of this study were to investigate (1) the frequencies the epitope-specific GAD65Abs and HLA-DR-DQ genes in LADY and (2) the association between HLA-DR-DQ genes and epitope-specific GAD65Abs. Higher frequencies of GAD65-CAb and multiepitope GAD65Abs were observed in young type 1 diabetes, LADY and old type 1 diabetes subjects than in latent autoimmune diabetes in adults (LADA) patients. The frequencies of the specific susceptible HLA haplotype DR3, total susceptible HLA haplotypes and high-risk genotypes were higher in type 1 diabetes and LADY patients than in LADA patients. In contrast, type 1 diabetes and LADY patients had lower frequencies of low/no genetic risk genotypes (DRX/X) than that of LADA patients. Logistic regression analysis suggested that the susceptible HLA haplotypes were risk factors for GADA multiepitope positivity in autoimmune diabetes mellitus. LADY may be more severe than LADA, and LADY seemed to be a transitional type of type 1 diabetes and LADA. GADA epitope and HLA-DR-DQ gene assays are important for risk stratification in autoimmune diabetes mellitus and protection of islet function.

6,058 views

13 citations